Fuad El Hibri

Emergent BioSolutions Announces That BioThrax (Anthrax Vaccine Adsorbed) Receives Market Authorization in India

Submitted by admin on Fri, 07/31/2009 - 23:03. categories [ ]

Emergent Biosolutions Expands Presence In Germany

Acquires Vivacs GmbH Along with Rights to Modified Vaccinia Virus Ankara (MVA) Strain and Monoclonal Vector Technology Platform (MVAtorTM)

Submitted by admin on Fri, 07/31/2009 - 13:03. categories [ ]

Emergent Biosolutions Announces Dr. Stephen Lockhart Joins Company To Lead Commercial Product Development Subsidiary

Dr. Lockhart Brings Top-Tier Pharma Leadership to Development of Company’s Commercial Product Portfolio

Submitted by admin on Mon, 07/06/2009 - 01:23. categories [ ]

Emergent Biosolutions Announces Management Changes

ROCKVILLE, MD, May 16, 2007—Emergent BioSolutions Inc. (NYSE: EBS) announced today the consolidation of the president and chief operating officer position.  With this change, Daniel J. Abdun-Nabi, the company’s president, will also take on the role of chief operating officer. In this combined role, Mr. Abdun-Nabi will oversee all of the company’s product development, manufacturing and corporate affairs activities.  Mr.

Submitted by admin on Mon, 07/06/2009 - 01:23. categories [ ]

Emergent Biosolutions Receives Development Contract From Niaid/Barda To Fund Continued Development Of Anthrax Therapeutic

$9.5 million development contract to fund non-clinical and clinical studies of anthrax immune globulin (AIG) over next 24 months

Submitted by admin on Mon, 07/06/2009 - 01:23. categories [ ]